On the metabolism of prostaglandin E1 administered intravenously to human volunteers

• Autorzy: Peskar B.A. , Cawello W. , Rogatti W. , Rudofsky G.
• Języki publikacji: EN

Abstrakty

EN

We have demonstrated recently the formation of a biologically active metabolite of prostaglandin (PG) E₁, 13,14-dihydro-PGE₁, during intravenous infusions of PGE₁ in patients with peripheral arterial occlusive disease. We have now investigated the levels of the immediate precursor of 13,14-dihydro-PGE₁ , the biologically inactive 15-keto-13,14-dihydro-PGE₁, during intravenous administration of 20 pig, 40pig or 80 pig PGE₁ over a period of 60 min to human volunteers. It was found that levels of 15-keto-13,14- -dihydro-PGE₁, but not those of PGEx itself, increased in a dose-dependent manner. Thus, increased formation of 13,14-dihydro-PGE₁ from 15-keto- 13,14-dihydro-PGE₁ with increasing doses of PGE₁ can be expected to occur. It remains to be investigated, to which extent formation of small amounts of 13,14-dihydro-PGE₁ during intravenous infusion of PGE₁ could contribute to the therapeutic effects of PGE₁ in patients with peripheral arterial occlusive disease.

Słowa kluczowe

EN

prostaglandin E1; intravenous infusion; plasma level; occlusive disease; peripheral arterial disease; patient; human lung

• Wydawca: -
• Czasopismo: Journal of Physiology and Pharmacology
• Rocznik: 1991
• Tom: 42
• Numer: 3
• Opis fizyczny: p.327-331,fig.,ref.

Twórcy

autor

Peskar B.A.

• Department of Parmacology and Toxicology, Ruhr-University of Bochum, D-4630 Bochum, Germany

autor

Cawello W.

• Schwarz Pharma AG, D-4019 Monheim, University of Essen, D-4300 Essen, Germany

autor

Rogatti W.

• Schwarz Pharma AG, D-4019 Monheim, University of Essen, D-4300 Essen, Germany

autor

Rudofsky G.

• Department of Internal Medicine, University of Essen, D-4300 Essen, Germany

Bibliografia

• 1. Carlson LA, Olsson AG. Intravenous prostaglandin E₁ in severe peripheral vasculaf disease. Lancet 1976; ii: 810.
• 2. Sinzinger H, Virgolini I, O’Grady J. Clinical trials of PGE₁ , PGI₂ and mimetics in patients with peripheral vascular disease. In: Prostaglandins in Clinical Research, (Schrör K and Sinzinger H, eds.) Alan Liss Inc, New York, 1989: 85-96.
• 3. Golub M, Zia P, Matsuno M, Horton R. Metabolism of prostaglandins A₁ and E₁ in man. J Clin Invest 1975; 56: 1404-1410.
• 4. Änggård E. The biological activity of three metabolites of prostaglandin E₁. Acta physiol scand 1966; 66: 509-510.
• 5. Westwick, J. The effect of pulmonary metabolites of prostaglandins E₁, E₁, E₂ and F₂α on ADP-induced aggregation of human and rabbit platelets. Br J Pharmacol 1976; 58: 297P-298P.
• 6. Hesse WH, Matamoros R, Horsch S, Peskar BA. On the metabolism of prostaglandin Ex in porcine lung homogenates and human circulation. In: Thrombosis and Haemorrhagic Disorders. Proc 6th Int Meeting Danubian League against Thrombosis and Haemorrhagic Disorders (Sinzinger H and Vinazzer H, eds.) 1989: 437-440.
• 7. Fitscha P, Simmet T, Peskar BA, Reuter H, Sinzinger H, Rogatti W, Tilsner V. Untersuchungen zur fibrinolytischen Aktivitat, Thrombozytenfunktion und Pharmakokinetik während intraarterieller oder intravenöser Prostaglandin-E₁-Infusion bei Patienten mit chronisch arterieller Verschlußkrankheit. Wien Klin Wochen sehr 1988; 100: 477-481.
• 8. Bothwell W, Verbürg M, Wynalda M, Daniels EG, Fitzpatrick FA. A radioimmunoassay for the unstable pulmonary metabolites of prostaglandin E₁ and E₂: An indirect index of their in vivo disposition and pharmacokinetics. J Pharmacol Exp Ther 1982; 220: 229-235.
• 9. Hamberg M, Samuelsson B: On the metabolism of prostaglandin E₁ and E₂ in man. J Biol Chem 1971; 246: 6713-6721.
• 10. Simmet Th, Peskar BA, Wolf HRD. On the metabolism of prostaglandin E₁ in patients suffering from arterial occlusive disease. In: Prostaglandin E₁ in Atherosclerosis (Sinzinger H, Rogatti W, eds.) Springer-Verlag, Heidelberg 1986: 8-12.